This figure presents data for the ROAR study (gray) and other studies in adults (blue) and the pediatric population (green). Data are presented for the COMBI-d study ( NCT01584648 ) for melanoma, BRF113928 ( NCT01336634 ) for NSCLC, NCT01723202 for differentiated thyroid cancer and ROAR ( NCT02034110 ) and NCI-MATCH ( NCT02465060 ) for the other tumor types. Pediatric data for gliomas and Langerhans cell histiocytosis are from the study NCT02124772, and those for LGGs are from the study NCT02684058 . Data for colorectal cancer are from the study NCT01072175 (data on file, Novartis). The NCT01584648 study included previously untreated patients; NCT01723202 included patients who were refractory to radioactive iodine; NCT01336634 included both previously treated and treatment-naive patients; and other studies included patients who previously received standard treatment. Patient numbers are the patients who received treatment with dabrafenib plus trametinib. The ORR for GIST ( n = 1) in the ROAR study was 0. Patients with melanoma, thyroid cancer, colorectal cancer and NSCLC were excluded in the NCI-MATCH study. This study included patients with BRAFV600E-positive tumors of the gastrointestinal tract ( n = 11), lung ( n = 5), CNS ( n = 5), myeloma ( n = 1), ameloblastoma of the mandible ( n = 1) and gynecologic malignancies ( n = 6). In the NCI-MATCH study, no CRs were observed; durable PRs were seen across a variety of tumor types, including papillary adenocarcinoma of the lung ( n = 5), low-grade serous ovarian carcinoma ( n = 5), mucinous-papillary serous adenocarcinoma of the peritoneum ( n = 1), histiocytic sarcoma of the brain ( n = 1), pleomorphic xanthoastrocytoma of the parietal lobe ( n = 1) and cholangiocarcinoma ( n = 4).
